Mandate

Vinge advises Isofol in conjunction with capital procurement

Vinge has advised Isofol Medical AB (publ), First North Growth Market Premier, in connection with its rights issue in the total amount of MSEK 150 and, conditional upon oversubscription in respect of the rights issue, a directed new issue of shares of a total amount of MSEK 30.

Isofol has convened an extraordinary general meeting which is proposed to grant authority to the board of directors to adopt resolutions concerning the new issues of shares. The rights issue is fully   underwritten through underwriting undertakings and guarantee obligations.

Vinge’s team primarily consisted of Anders StridWibeke SorlingJenny Sandlund (all Capital Markets) as well as Victor Ericsson and Emelie Svanberg (Tax).

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026